Cost-effectiveness of nucleoside analog therapy for hepatitis B in china: A markov analysis

Value in Health

Volumn 13, Issue 5, 2010, Pages 592-600

  Wu, Bin ^a   Li, Te ^b   Chen, Huafeng ^a   Shen, Jinfang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Yuxi People Hospital   (China)

Author keywords

China; chronic hepatitis B; cost effectiveness; nucleoside analogs

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B ANTIGEN; LAMIVUDINE; TELBIVUDINE;

ADULT; ARTICLE; CHINA; CHRONIC HEPATITIS; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; ECONOMIC ASPECT; HEALTH STATUS; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MONOTHERAPY; MONTE CARLO METHOD; MORTALITY; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SEROCONVERSION;

EID: 77955363219     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2010.00733.x     Document Type: Article

References (28)

1. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004 350 : 1118 1129.
2. Yuan Y, Iloeje U, Li H, et al. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program. Value Health 2008 11 (Suppl. 1 S11 22.
3. Chen CJ, Yang HI, Iloeje UH. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009 49 (Suppl. S72 84.
4. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008 359 : 1486 1500.
5. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007 45 : 507 539.
6. Liaw YF, Nancy L, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008 2 : 263 283.
7. Buti M, Brosa M, Casado MA, et al. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol 2009 51 : 640 646.
8. Spackman DE, Veenstra DL. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Pharmacoeconomics 2008 26 : 937 949.
9. Veenstra DL, Spackman DE, Di Bisceglie A, et al. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. Aliment Pharmacol Ther 2008 27 : 1240 1252.
10. Veenstra DL, Sullivan SD, Clarke L, et al. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics 2007 25 : 963 977.
11. Lacey LF, Gane E. The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore. J Viral Hepat 2007 14 : 751 766.
12. Kanwal F, Gralnek IM, Martin P, et al. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005 142 : 821 831. (Pubitemid 40664041)
13. Dienstag JL. Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology 2009 49 (Suppl. S112 21.
14. Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology 2009 99 (Suppl. S103 11.
15. Lin YT, Liu YH. Epidemiological study of hepatitis B in 1990-2003 in Wuxi City, Jiangsu Province. Zhonghua Liu Xing Bing Xue Za Zhi 2004 25 : 1083.
16. European Association for the Study of the L. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009 50 : 227 242.
17. Zhiqiang G, Zhaohui D, Qinhuan W, et al. Cost of chronic hepatitis B infection in China. J Clin Gastroenterol 2004 389 (Suppl. S175 8.
18. Gao Q. Economic analysis for liver and renal transplant in a transplant center. 2007 1 46. China Master's Theses Full-Text Database. Available from: http://www.cnki.net [Accessed April 22, 2009 AR, Kowdley KV, Iloeje U, et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health 2008 11 : 527 538.
19. Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 1985 5 : 157 177.
20. Barton GR, Briggs AH, Fenwick EA. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Health 2008 11 : 886 897.
21. Custer B, Sullivan SD, Hazlet TK, et al. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004 38 (Suppl. S158 68.
22. Chen CJ, Wang LY, Yu MW. Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J Gastroenterol Hepatol 2000 15 (Suppl. SE3 6.
23. Sun X, Qin WX, Li YP, et al. Comparative cost-effectiveness of antiviral therapies in patients with chronic hepatitis B: a systematic review of economic evidence. J Gastroenterol Hepatol 2007 22 : 1369 1377.
24. Enriquez AD, Campbell MS, Reddy KR. Cost-effectiveness of suppressing hepatitis B virus DNA in immune tolerant patients to prevent hepatocellular carcinoma and cirrhosis. Aliment Pharmacol Ther 2007 26 : 383 391.
25. Veenstra DL, Sullivan SD, Lai MY, et al. HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan. Value Health 2008 11 : 131 138.
26. Schiff E, Simsek H, Lee WM, et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 2008 103 : 2776 2783.
27. Xu WM, Cui YT, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009 16 : 94 103.
28. Papatheodoridis GV, Cholongitas E, Archimandritis AJ, et al. Current management of hepatitis B virus infection before and after liver transplantation. Liver Int 2009 29 : 1294 1305.